Trial Profile
An open label,multicenter study assessing efficacy and safety of Dolutegravir/Rilpivirine who switched from any other antiretroviral combination
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 30 Dec 2016
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Rilpivirine (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 30 Dec 2016 New trial record